MXPA01011344A - El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. - Google Patents

El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.

Info

Publication number
MXPA01011344A
MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
protein tyrosine
prophylactic
kinase pathway
therapeutic treatment
Prior art date
Application number
MXPA01011344A
Other languages
English (en)
Inventor
Juan Eugene De Jr
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of MXPA01011344A publication Critical patent/MXPA01011344A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion esta dirigida a un metodo para el tratamiento profilactico y terapeutico de la degeneracion macular relacionada con la edad asi como a metodos para el tratamiento profilactico y terapeutico de las complicaciones exudativas y atroficas de la degeneracion macular relacionada con la edad. Los metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente para tratar al animal respecto a la degeneracion macular relacionada con la edad o a una complicacion exudativa o atrofica de la misma, respectivamente, en forma profilactica o terapeutica. La presente invencion provee tambien un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la retina, un metodo para el tratamiento profilactico y terapeutico de la degeneracion de la coroide y un metodo para el tratamiento profilactico y terapeutico del engrosamiento de la membrana de Bruch. Estos metodos implican la administracion de un inhibidor de la ruta de la proteina tirosina quinasa a un animal, tal como un mamifero, en particular un humano, en una cantidad suficiente par tratar la macula, retina, coroide o membrana de Bruch, respectivamente, en forma profilactica o terapeutica. De preferencia el inhibidor de la ruta de la proteina tirosina quinasa es genisteina o un analogo o profarmaco de la misma o una sal farmaceuticamente aceptable de cualquiera de los anteriores.
MXPA01011344A 1999-05-07 2000-05-05 El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. MXPA01011344A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US35044099A 1999-07-09 1999-07-09
PCT/US2000/012339 WO2000067738A2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MXPA01011344A true MXPA01011344A (es) 2004-06-03

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011344A MXPA01011344A (es) 1999-05-07 2000-05-05 El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.

Country Status (6)

Country Link
EP (1) EP1178791A2 (es)
JP (1) JP4920134B2 (es)
AU (1) AU774495B2 (es)
CA (1) CA2373178C (es)
MX (1) MXPA01011344A (es)
WO (1) WO2000067738A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN111655151B (zh) * 2018-01-25 2024-03-22 国立大学法人大阪大学 压力状态的检测方法以及压力检测装置
CN114931574A (zh) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 一种铁死亡抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (ja) * 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
CA2514681C (en) * 1996-11-05 2011-04-05 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
WO1998040090A1 (en) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methods for inhibiting bacterial cytotoxicity
JP2001518470A (ja) * 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
AU756515B2 (en) * 1998-03-13 2003-01-16 Johns Hopkins University School Of Medicine, The The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Also Published As

Publication number Publication date
WO2000067738A3 (en) 2001-08-23
AU4988400A (en) 2000-11-21
CA2373178A1 (en) 2000-11-16
CA2373178C (en) 2013-07-02
WO2000067738A2 (en) 2000-11-16
EP1178791A2 (en) 2002-02-13
AU774495B2 (en) 2004-07-01
JP4920134B2 (ja) 2012-04-18
JP2002544159A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
Gros Spasticity—clinical classification and surgical treatment
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
CA2213833A1 (en) Vascular endothelial cell growth factor antagonists
EP2514420A3 (en) Use of rapamycin for the treatment or prevention of age-related macular degeneration
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
IL175875A0 (en) Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
NO970517L (no) Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
CA2314571A1 (en) Methods and compositions for treating diseases and conditions of the eye
CA2262268C (en) Method of treating impotence due to spinal cord injury
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
MXPA03001160A (es) Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico.
EP1037622A4 (en) TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS
IT1276462B1 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
ATE325618T1 (de) Verwendung des nervenwachstumfaktors zur herstellung eines arzneimittels zur behandlung von erkrankungen der innenaugegeweb
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
WO2004087157A3 (en) Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration